Complications of a temozolomide overdose: A case report

Journal of Neuro-Oncology

Volumn 80, Issue 1, 2006, Pages 57-61

  Spence, Alexander M ^a   Kiem, Hans Peter ^a   Partap, Sonia ^a   Schuetze, Scott ^a   Silber, John R ^a   Peterson, Richard A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma multiforme; Overdose; Temozolomide; Toxicity

Indexed keywords

CARBAMAZEPINE; CEFTAZIDIME; CLINDAMYCIN; ETOPOSIDE; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMIPENEM; ISOTRETINOIN; LEVOFLOXACIN; MEROPENEM; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RECOMBINANT ERYTHROPOIETIN; TEMOZOLOMIDE; TOPIRAMATE; VANCOMYCIN;

ACNE; ADULT; ANAMNESIS; ARTICLE; BACTEREMIA; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CASE REPORT; CELLULITIS; CLINICAL FEATURE; CONFUSION; DEJA VU; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG ERUPTION; DRUG OVERDOSE; ENTEROBACTER INFECTION; ENZYME ACTIVITY; FOLLOW UP; GAMMA KNIFE; GLIOBLASTOMA; GRAND MAL SEIZURE; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCYTOPENIA; SERRATIA; SUPERINFECTION; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING;

EID: 33749174767     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9152-y     Document Type: Article

References (19)

1. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5:807-814
2. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
3. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291
4. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A:2236-2241
5. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67:1299-1302
6. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Rev 23:35-61
7. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ (1997) Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3:1093-1100
8. Rudek MA, Donehower RC, Statkevich P, Batra VK, Cutler DL, Baker SD (2004) Temozolomide in patients with advanced cancer: Phase I and pharmacokinetic study. Pharmacotherapy 24:16-25
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
10. 6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 2:735-741
11. 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 7:421-428
12. Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 21:5427-5440
13. Brandes AA, Palmisano V, Pasetto LM, Basso U, Monfardini S (2001) High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest 19:41-48
14. Durando X, Lemaire JJ, Tortochaux J, Van-Praagh I, Kwiatkowski F, Vincent C, Bailly C, Verrelle P, Irthum B, Chazal J, Bay JO (2003) High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: A retrospective analysis of 114 patients. Bone Marrow Transplant 31:559-564
15. Fine HA, Antman KH (1992) High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: Therapeutic rationale and clinical experience. Bone Marrow Transplant 10:315-321
16. Mbidde EK, Selby PJ, Perren TJ, Dearnaley DP, Whitton A, Ashley S, Workman P, Bloom HJ, McElwain TJ (1988) High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 58:779-782
17. Adkins DR, Irvin R, Kuhn J, Boldt DH, Roodman GD, Salzman D, Freytes C, Von Hoff DD, LeMaistre CF (1993) A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. Invest New Drugs 11:169-179
18. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178-7187
19. Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem HP (2005) Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105:997-1002